San Antonio Breast Cancer Symposium | Conference

Dr. Joanne Blum on the EMBRACA Trial in Metastatic BRCA-Mutant Breast Cancer

December 11th 2015

Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.

T-DM1 Extends Survival in Heavily Pretreated HER2+ Breast Cancer

December 11th 2015

T-DM1 (ado-trastuzumab emtansine; Kadcyla) reduced the risk of death by 32% and improved median overall surviva by almost 7 months compared with physician's choice of therapy in heavily pretreated patients with HER2-positive advanced breast cancer.

Buparlisib Modestly Improves PFS in HR-Positive Advanced Breast Cancer

December 11th 2015

Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.

Dr. Saeed Rafii on Atezolizumab/ Nab-paclitaxel in TNBC

December 11th 2015

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).

APOBEC3B Overexpression Linked to Tamoxifen Resistance

December 11th 2015

The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.

Estrogen Receptor Mutations Linked to Lower Survival in HR+/HER2- Breast Cancer

December 11th 2015

Estrogen receptor mutations are prevalent and associated with poorer survival in patients with pretreated HR+/HER2- metastatic breast cancer.

Study Links pCR After Neoadjuvant Therapy to Improved Survival in TNBC

December 10th 2015

Achieving a pCR with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab was associated with a survival improvement in patients with triple-negative breast cancer.

Complications, Costs Higher With Mastectomy Versus Lumpectomy for Early Breast Cancer

December 10th 2015

The risk of complications from mastectomy plus reconstruction was increased by two-fold compared with lumpectomy plus whole breast irradiation, after adjustment for other treatment differences.

Survival Better With Breast-Conserving Therapy Versus Mastectomy in Early-Stage Cancers

December 10th 2015

Women who opt for breast-conserving therapy and radiation to treat their early-stage breast cancer are about 20% more likely to be alive after 10 years compared with their counterparts who had mastectomy.

Reuben Harris on How Tamoxifen Resistance May be Driven by APOBEC3B

December 10th 2015

Reuben S. Harris, PhD, investigator Howard Hughes Medical Institute and professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.

Atezolizumab/Nab-Paclitaxel Combo Shows High Response Rates in TNBC

December 10th 2015

Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.

Neoadjuvant Carboplatin Improves Disease-Free Survival in Triple-Negative Breast Cancer

December 10th 2015

Adding carboplatin to neoadjuvant chemotherapy improves disease-free survival significantly in women with triple-negative breast cancer but not HER2-positive breast cancer.

Dr. Whitworth on the Importance of Additional HER2 Subtyping

December 10th 2015

Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.

Dr. Goetz on Adjuvant Capecitabine Following Neoadjuvant Chemotherapy and Surgery

December 10th 2015

Matthew Goetz, MD, medical oncologist, professor of Oncology, associate professor of Pharmacology, andprofessor of Pharmacology at Mayo Clinic, discusses a phase III study looking at capecitabine (Xeloda) in patients with residual breast cancer following neoadjuvant chemotherapy and surgery.

Avelumab Effective in PD-L1-Positive Metastatic Breast Cancer

December 9th 2015

Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.

Adjuvant Chemotherapy May Not Improve Outcomes in Luminal A Breast Cancer

December 9th 2015

Premenopausal women with high-risk breast cancer of the luminal A subtype derive no benefit from adjuvant chemotherapy.

Denosumab Demonstrates Survival Benefit in Postmenopausal Women

December 9th 2015

A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.

Adjuvant Capecitabine Improves Survival in HER2-Negative Breast Cancer

December 9th 2015

Adding capecitabine to adjuvant therapy reduced the risk of disease recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer following neoadjuvant chemotherapy and surgery.

Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

December 19th 2014

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Dr. Gradishar Discusses the Results of the BOLERO-1 Trial

December 17th 2014

William J. Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses the BOLERO-1 Trial.

NEXT PAGE
PREVIOUS PAGE